Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB
Status:
Completed
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
In recent years, vitamin D (VD) has received much attention in the fields of host immune
regulation, inflammation, fibrosis, cell proliferation and differentiation and tumor. VD
works by binding to the vitamin D receptor (VDR). VDR is mainly distributed in giant cells,
dendritic cells, T cells and lymphocytes. Four SNPs of VDRS have been most studied: TaqI
(rs731236), FokI (rs10735810), ApaI (rs7975232), and BsmI (rs1544410). At present, more and
more patients have been treated with oral nucleotide/nucleoside analogues (NAs) with direct
antiviral drugs in China, and a large part of them show low expression of HBsAg. Clinical
cure can be pursued for these patients, that is, HBsAg turns negative. A number of studies
have been carried out at home and abroad.
In this study, We will recruit CHB patients with low HBsAg levels. They all will receive
pegylated interferon treatment and were randomly assigned to a vitamin D treatment or a
control group. A final assessment will be made to determine whether vitamin D levels would
affect the clearance rate of HBsAg.